66 related articles for article (PubMed ID: 38490714)
1. Engineering of CD34+ progenitor-derived natural killer cells with higher-affinity CD16a for enhanced antibody-dependent cellular cytotoxicity.
van Hauten PMM; Hooijmaijers L; Vidal-Manrique M; van der Waart AB; Hobo W; Wu J; Blijlevens NMA; Jansen JH; Walcheck B; Schaap NPM; de Jonge PKJD; Dolstra H
Cytotherapy; 2024 Mar; 26(3):252-260. PubMed ID: 38127030
[TBL] [Abstract][Full Text] [Related]
2. iPSC-derived natural killer cells expressing the FcγR fusion CD64/16A can be armed with antibodies for multitumor antigen targeting.
Snyder KM; Dixon KJ; Davis Z; Hosking M; Hart G; Khaw M; Matson A; Bjordahl R; Hancock B; Shirinbak S; Miller JS; Valamehr B; Wu J; Walcheck B
J Immunother Cancer; 2023 Dec; 11(12):. PubMed ID: 38056893
[TBL] [Abstract][Full Text] [Related]
3. In Vivo PET Imaging of
Pham TT; Chenoweth A; Patel N; Banu A; Osborn G; Blower PJ; Karagiannis SN; Ma MT
J Nucl Med; 2024 Jun; ():. PubMed ID: 38844362
[TBL] [Abstract][Full Text] [Related]
4. Enhanced IL-15-mediated NK cell activation and proliferation by an ADAM17 function-blocking antibody involves CD16A, CD137, and accessory cells.
Matson AW; Hullsiek RH; Dixon KJ; Wang S; Lindstedt AJ; Friess RR; Phung SK; Freedman TS; Felices M; Truckenbrod EN; Wu J; Miller JS; Walcheck B
bioRxiv; 2024 May; ():. PubMed ID: 38798522
[TBL] [Abstract][Full Text] [Related]
5. TGF-β signalling limits effector function capacity of NK cell anti-tumour immunity in human bladder cancer.
Wong JKM; McCulloch TR; Alim L; Omer N; Mehdi AM; Tuong ZK; Bonfim-Melo A; Chung E; Nicol A; Simpson F; Rhee H; Rossi GR; Souza-Fonseca-Guimaraes F
EBioMedicine; 2024 May; 104():105176. PubMed ID: 38810560
[TBL] [Abstract][Full Text] [Related]
6. A tri-specific killer engager against mesothelin targets NK cells towards lung cancer.
Kennedy PR; Vallera DA; Ettestad B; Hallstrom C; Kodal B; Todhunter DA; Bendzick L; Hinderlie P; Walker JT; Pulkrabek B; Pastan I; Kratzke RA; Fujioka N; Miller JS; Felices M
Front Immunol; 2023; 14():1060905. PubMed ID: 36911670
[TBL] [Abstract][Full Text] [Related]
7. Recombinant Antibodies to Arm Cytotoxic Lymphocytes in Cancer Immunotherapy.
Koch J; Tesar M
Transfus Med Hemother; 2017 Sep; 44(5):337-350. PubMed ID: 29070979
[TBL] [Abstract][Full Text] [Related]
8. Hiding from allogeneic NK cells and macrophages by a synthetic receptor.
Hotta A; Lee J
Cell Stem Cell; 2023 Nov; 30(11):1393-1394. PubMed ID: 37922874
[TBL] [Abstract][Full Text] [Related]
9. Role of Fcγ receptors in HER2-targeted breast cancer therapy.
Musolino A; Gradishar WJ; Rugo HS; Nordstrom JL; Rock EP; Arnaldez F; Pegram MD
J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 34992090
[TBL] [Abstract][Full Text] [Related]
10. Antibody-Dependent Cell-Mediated Cytotoxicity Through Natural Killer (NK) Cells: Unlocking NK Cells for Future Immunotherapy.
Chin DS; Lim CSY; Nordin F; Arifin N; Jun TG
Curr Pharm Biotechnol; 2022; 23(4):552-578. PubMed ID: 34414871
[TBL] [Abstract][Full Text] [Related]
11. Bispecific immune cell engager enhances the anticancer activity of CD16+ NK cells and macrophages in vitro, and eliminates cancer metastasis in NK humanized NOG mice.
Khoshtinat Nikkhoi S; Yang G; Owji H; Grizotte-Lake M; Cohen RI; Gil Gonzalez L; Massumi M; Hatefi A
J Immunother Cancer; 2024 Mar; 12(3):. PubMed ID: 38490714
[TBL] [Abstract][Full Text] [Related]
12. Bispecific killer cell engager with high affinity and specificity toward CD16a on NK cells for cancer immunotherapy.
Nikkhoi SK; Li G; Eleya S; Yang G; Vandavasi VG; Hatefi A
Front Immunol; 2022; 13():1039969. PubMed ID: 36685519
[TBL] [Abstract][Full Text] [Related]
13. Tribody [(HER2)
Oberg HH; Kellner C; Gonnermann D; Sebens S; Bauerschlag D; Gramatzki M; Kabelitz D; Peipp M; Wesch D
Front Immunol; 2018; 9():814. PubMed ID: 29725336
[TBL] [Abstract][Full Text] [Related]
14. Targeting natural killer cells to acute myeloid leukemia in vitro with a CD16 x 33 bispecific killer cell engager and ADAM17 inhibition.
Wiernik A; Foley B; Zhang B; Verneris MR; Warlick E; Gleason MK; Ross JA; Luo X; Weisdorf DJ; Walcheck B; Vallera DA; Miller JS
Clin Cancer Res; 2013 Jul; 19(14):3844-55. PubMed ID: 23690482
[TBL] [Abstract][Full Text] [Related]
15. Improved Detection of
Katano I; Ito R; Kawai K; Takahashi T
Front Immunol; 2020; 11():532684. PubMed ID: 33117338
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
